The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Open accessAbstract
The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient’s tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–215 of 215
Amaral, S., Moura, M. C., Carvalho, J., Chaves, A., Jesus, E., & Sousa, G. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz027.004 · Cited by 30
Giommoni, E., Giorgione, R., Paderi, A., Pellegrini, E., Gambale, E., Marini, A., Antonuzzo, A., Marconcini, R., Roviello, G., Matucci‐Cerinic, M., et al. (2021) · Immuno · doi:10.3390/immuno1030017 · Cited by 30
Shirasawa, M., Yoshida, T., Imabayashi, T., Okuma, K., Matsumoto, Y., Masuda, K., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.013 · Cited by 30
A narrative review of five multigenetic assays in breast cancer
Zeng, C., & Zhang, J. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-1920 · Cited by 30
Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine
Paolillo, C., Londin, E. R., & Fortina, P. M. (2016) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2016.1210331 · Cited by 24
Clinicopathologic features and treatment advances in cancers with HER2 alterations
Cen, S., Liu, Z., Pan, H., & Han, W. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188605 · Cited by 23
Barrow, E., Evans, D. G., McMahon, R. F., Hill, J., & Byers, R. J. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2010.084418 · Cited by 20
Gene expression signatures in early breast cancer: Better together with clinicopathological features
Oliveira, L. J. D. C., Amorim, L. C., Megid, T. B. C., de Resende, C. A. A., & Mano, M. S. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103708 · Cited by 20
Shepherd, D. J., Tabb, E. S., Kunitoki, K., Zhang, M. L., Kem, M., Barth, J. L., Qualls, D. A., Mooradian, M. J., Gainor, J. F., Mino-Kenudson, M. A., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00974-9 · Cited by 17
Ranganath, H., Jain, A., Smith, J. R., Ryder, J., Chaudry, A., Miller, E., Hare, F., Valasareddy, P., Seitz, R. S., Hout, D. R., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09470-y · Cited by 17
Development and validation of blood tumor mutational burden reference standards
Raiber, E., Portella, G., Butler, M. G., Clement, O. O., Konigshofer, Y., & Hadfield, J. (2022) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23100 · Cited by 11
Blatt, S., Kämmerer, P. W., Krüger, M., Surabattula, R., Thiem, D. G. E., Dillon, S. T., Al‐Nawas, B., Libermann, T. A., & Schuppan, D. (2023) · Cancers · doi:10.3390/cancers15072071 · Cited by 11
Cohen, R., Lee‐Pullen, T. F., Miller, T. J., Meehan, K. L., Fuller, K. A., & McCoy, M. J. (2023) · Methods · doi:10.1016/j.ymeth.2023.09.004 · Cited by 10
Anagnostou, V., Ho, C., Wheatley‐Price, P., Laurie, S. A., Taylor, J., Sacher, A. G., Brahmer, J., Gallinaro, L., Ding, K., & Dancey, J. E. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.219 · Cited by 3
Uematsu, M., Narita, K., Sato, T., & Hosomi, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-967835/v1 · Cited by 1
Cited by
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Mechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects
Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117535 · Cited by 119
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
Metadata
- Authors
- Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2024-03
- Volume
- 187
- Issue
- 7
- Pages
- 1617-1635
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W4393251590
- Cited by
- 672
- References
- 215
- FWCI
- 102.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.